tommyc said...
http://www.news-medical.net/news/20121013/Curcumin-can-inhibit-formation-of-prostate-cancer-metastases.aspx
This looks interesting
That was interesting. Animal models, mouse specifically. Though some folks claim mice are very lucky, everything works on them, LOL! Interestingly, they 1st looked at breast cancer, and then at PC. Apparently helped with both via the same mechanism.
"Breast and prostate cancers are often associated with latent or chronic inflammatory reactions, and in both cases, the tumor cells were found to produce pro-inflammatory immunomodulators including the cytokines CXCL1 und CXCL2. ............The researchers went on to show that curcumin specifically decreases the expression of these two proteins, and in a mouse model, this effect correlated with a decline in the incidence of metastases. "Due to the action of curcumin, the tumor cells synthesize smaller amounts of cytokines that promote metastasis," says Bachmeier. "As a consequence, the frequency of metastasis formation in the lungs is significantly reduced, in animals with breast cancer, as we showed previously, or carcinoma of the prostate, as demonstrated in our new study."...................Curcumin and chemoprevention
Bachmeier therefore believes that curcumin may be useful in the prevention of breast and prostate cancers - which are both linked to inflammation - and in reducing their metastatic potential. "This does not mean that the compound should be seen as a replacement for conventional therapies. However, it could play a positive role in primary prevention - before a full-blown tumor arises - or help to avert formation of metastases. In this context the fact that the substance is well tolerated is very important, because one can safely recommend it to individuals who have an increased tumor risk." ............................
The agent might also be valuable as a supplement to certain cancer therapies. At all events, curcumin's beneficial effects must first be confirmed in controlled clinical tests. Bachmeier is now planning such a trial in patients who suffer from therapy-resistant carcinoma of the prostate. "
Wonder if the controlled clinical test was completed yet, since the above was back in 2012?